menu search

COLL / Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates

Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates
Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing innovative treatments for chronic pain with abuse-deterrent technology. The company's financials show solid sales momentum, decreased operating expenses, improved profitability, and increased cash position. Collegium's product lineup includes Xtampza ER, Nucynta IR, and candidates in clinical development, all utilizing the company's DETERx technology. Read More
Posted: Aug 12 2023, 05:25
Author Name: Seeking Alpha
Views: 102067

COLL News  

Collegium Pharmaceutical: Delivering On Promises

By Seeking Alpha
October 24, 2023

Collegium Pharmaceutical: Delivering On Promises

Today, we revisit Collegium Pharmaceutical, Inc., which has seen a 30% increase in its stock price since our last look at it in June 2022. Collegium P more_horizontal

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

By Zacks Investment Research
October 6, 2023

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Neverthe more_horizontal

Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates

By Seeking Alpha
August 12, 2023

Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates

Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing innovative treatments for chronic pain with abuse-deterrent techn more_horizontal

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q2 Earnings

By Zacks Investment Research
August 3, 2023

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q2 Earnings

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2023, it might b more_horizontal

Collegium Pharmaceutical, Inc. (COLL) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 6, 2023

Collegium Pharmaceutical, Inc. (COLL) Q1 2023 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Christopher James - Vice Pr more_horizontal

Collegium Pharmaceutical, Inc. (COLL) Q4 2022 Earnings Call Transcript

By Seeking Alpha
February 23, 2023

Collegium Pharmaceutical, Inc. (COLL) Q4 2022 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Christopher James - V more_horizontal

Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates

By Zacks Investment Research
February 23, 2023

Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 5.83% and 2%, respectively, for the quarter ended December 2022. Do the nu more_horizontal

Collegium Pharmaceutical: Changing My Strategy After Q3 Earnings Beat

By Seeking Alpha
November 9, 2022

Collegium Pharmaceutical: Changing My Strategy After Q3 Earnings Beat

My Collegium Pharmaceutical position has been gathering thanks to the ticker trading between my Buy and Sell Targets. The company's Q3 earnings beat h more_horizontal


Search within

Pages Search Results: